glp-1 obesity drug market size 2025 The United States Agonists Weight Loss Drugs & Outlook, 2030 Chart: 1 in 8 Americans

We also found that cost remains a substantial barrier to sustained use, with nearly 13% of patients citing affordability as a reason for stopping

[DOI] [PMC free article] [PubMed] [Google Scholar] 212.Sathananthan A., Man C.D., Micheletto F., Zinsmeister A.R., Camilleri M., Giesler P.D

10.1007/s12325-009-0014-9 182 TanX.HuJ

[DOI] [PubMed] [Google Scholar] 57.Witkowski M., Moreno S.I., Fernandes J., Johansen P., Augusto M., Nair S

GLP-1 controls specific types of appetite rather than baseline hunger

Retatrutide and placebo demonstrated a clear difference in fat content, establishing that the drugs primary activity is on fat, not muscle